(based on 1,274 customer ratings)
Click on the links below to preview selected pages from this course.
- Therapeutic Drug Monitoring Definition
- Pharmacogenomics Definition
- Basic Pharmacokinetics
- Drug Concentration Over Time
- Drug Metabolism
- Drug Elimination
- Protein Binding
- Protein Availability and Drug Dosing
- Other Factors Affecting Drug Absorption and Distribution
- Given what you have learned thus far, which of the following statements below do you think is true?
- Steady State
- Steady State Example
- Peak and Trough Sampling Times
- Why TDM?
- Why TDM?
- Why TDM?
- Unexpected Concentrations
- A physician needs to prescribe a drug to a patient but the drug has a narrow therapeutic window. He is concerned about possible toxic effects. To asse...
- TDM For All Drugs?
- When is TDM Not Useful?
- Alternative to TDM
- Examples of Drugs That are Monitored by TDM
- TDM for Antibiotics
- TDM for Anticonvulsants
- TDM for Immunosuppressants
- TDM for Cardiac Medications
- TDM for Theophylline
- Albuterol is a fast-acting bronchodilator used acutely during asthma attacks. Which of the reasons below explains why TDM for albuterol is not availab...
- Laboratory Methods
- Individualized Medicine
- Polymorphism and CYP450
- Enzyme Abnormalities and Drugs
- Clinical Utility
- Warfarin Metabolism
- Warfarin Metabolism, continued
- A person who is classified as an ultrarapid metabolizer (UM) would need __________ of a drug metabolized by that enzyme.
- CYP450 Induction and Inhibition
- CYP450 Induction and Inhibition, continued
- A patient is taking cimetidine for a stomach ulcer. This drug inhibits CYP2D6. The patient is now prescribed amphetamine for narcolepsy. Amphetamine i...
- Genotype versus Phenotype
- Genotype versus Phenotype, continued
- TDM and PGx
- The Bottom Line
- The Bottom Line, continued
Level of instruction: Intermediate
Intended Audience: Clinical laboratory technologists and technicians as well as other health care personnel who are responsible for prescribing and administering therapeutic medications.
Author Credentials: Kevin F. Foley, PhD, DABCC, MT, SC earned his B.S. degree in History and Political Science before going on to complete additional courses and a one-year clinical internship in Medical Technology, earning ASCP certification as a medical technologist with further certification as a specialist in clinical chemistry. Following this training, Kevin earned his PhD in clinical pharmacology and toxicology at East Carolina School of Medicine in North Carolina. He then worked over four years as an assistant professor at the University of Vermont in the Departments of Medical Laboratory and Radiation Sciences as well and Pharmacology. Kevin then went on to train and work as an assistant professor and clinical chemist at the Mayo Clinic in Rochester Minnesota. He then served as head of the Clinical Laboratory Sciences Department at Northern Michigan University. Currently, Kevin is the Northwest chemistry, toxicology, immunology and POC director for Kaiser Permanente. He continues to teach pharmacology, clinical chemistry, immunology and medicinal chemistry at Oregon Health Sciences University. His research areas include cardiovascular risk and inflammation markers as well as the neuropharmacology of amphetamine-like compounds. Kevin is very active in the American Association of Clinical Chemistry.